Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GPC Biotech begins early trial of anticancer compound
The primary objective of this study is to determine the maximum tolerated dose for satraplatin in combination with Xeloda in patients with advanced solid tumors. The trial is
The primary objective of this study is to determine the maximum tolerated dose for satraplatin in combination with Xeloda in patients with advanced solid tumors. The trial is
The new approval expands the indication for the drug, which is already approved for use in the treatment of partial onset epileptic seizures. Juvenile myoclonic epilepsy (JME) is
The single-dose, dose-escalating phase I study examined the safety and tolerability of a single injection of the drug in 24 healthy volunteers. Biothera plans to initiate a multiple-dose,
Vilazodone is being developed along with a potential companion biomarker test that will be developed by the PGxHealth division of Clinical Data. Clinical Data plans to issue the
“There are 20 million children and adults living with diabetes in the US, and many of them are undiagnosed until they develop complications,” said Howard Birndorf, Nanogen chairman
Professor Gareth Morris of the school of chemistry and Professor Risto Kauppinen of the University of Birmingham are to lead the development of a new non-invasive technique which
The open label trial is expected to enroll approximately 50 patients with advanced solid tumors or refractory lymphomas at two trial sites – MD Anderson Cancer Center and
The terms of the licenses consist of a single upfront payment to Novogen of $1 million, a series of payments for each compound upon reaching the milestones of
The study, published in the journal Carcinogenesis, is the first to suggest that a “negative energy balance” – produced by increasing the mice's energy output by use of
The European Zomaxx study is a single-arm trial that will evaluate the safety and performance of the Zomaxx zotarolimus-eluting stent in patients with single or two-vessel coronary artery